๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hefei
Clinical trial register · China

Clinical Trials in Hefei, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Anhui Provincial Hospital55 Merck Sharp & Dohme LLC36 Anhui Medical University29 AstraZeneca27 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.25
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Hefei

875 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Programmed Cell Death Ligand 1 PET/CT in Various PD-L1-Related Disease Patients
NCT07618936PD-L1 Gene Mutation, PD-L1 Gene Amplification, PD-L1-related Disease, Positron Emission Tomography
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2026-06-01
Recruiting
China Metastatic Liver Cancer Clinical Registry Cohort Database
NCT07602504Liver Metastases, Metastases to Liver, Liver Cancer, Neoplasms
Anhui Provincial Hospital
Observational
2,000
Bengbu, Hefei, Qingdao
2026-06-01
Recruiting
An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer
NCT07667751Ovary Cancer
Bai-Rong Xia
Phase 2
35
Hefei
2026-06-01
Not yet open
NK521 in the Treatment of Advanced Solid Tumors
NCT07657416Hepatocellular Carcinoma (HCC), Ovarian Cancer, Malignant Ascites
Base Therapeutics (Shanghai) Co., Ltd.
Phase EARLY_PHASE1
18
Hefei
2026-06
Not yet open
The Effect of Esketamine on Cough Reflex During Tracheal Extubation in Patients Undergoing Non-inflatable Transoral Endoscopic Thyroid Surgery
NCT07641673Thyroidectomy, Coughing Reflex
The Second Hospital of Anhui Medical University
Not applicable
186
Hefei
2026-06
Not yet open
Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
NCT07569757Multiple Myeloma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
260
Bengbu, Hefei, Beijing, Chongqing, Lanzhou, Guangzhou, Zhanjiang, Nanning
2026-06
Not yet open
The Effect of Esketamine on Cough Reflex During Tracheal Extubation in Patients Undergoing Open Thyroid Surgery
NCT07625826Thyroidectomy, Coughing Reflex
The Second Hospital of Anhui Medical University
Not applicable
136
Hefei
2026-06
Not yet open
Differences in Pelvic Floor Motion Level Among Chinese Women and Construction of an Assessment System
NCT07608146Stress Urinary Incontinence (SUI)
Peking Union Medical College Hospital
Observational
2,000
Hefei, Beijing, Linxia, Qinzhou, Guiyang, Zunyi, Tangshan, Mudanjiang
2026-05-30
Recruiting
Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
NCT06993506HER2-negative Breast Cancer, Recurrence, Metastasis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
500
Hefei, Beijing, Fuzhou, Xiamen, Shijiazhuang, Zhengzhou, Shiyan, Wuhan
2026-05-28
Recruiting
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPROยฎ in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
NCT07477587Multiple Myeloma (MM)
Shanghai Henlius Biotech
Phase 1
258
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Meizhou
2026-05-27
Recruiting
Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity
NCT07785934Drug Drug Interaction (DDI), Pharmacokinetics and Pharmacodynamics
The United Bio-Technology (Hengqin) Co., Ltd.
Phase 1
48
Hefei
2026-05-27
Recruiting
Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.
NCT07279935Non-small Cell Lung Cancer
AstraZeneca
Phase 4
100
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan
2026-05-26
Recruiting
A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
NCT07547553Advanced or Unresectable Hepatocellular Carcinoma (HCC)
Huahui Health
Phase 1/2
30
Bengbu, Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou
2026-05-19
Recruiting
Adaptive DBS for PD
NCT07635823Parkinson Disease(PD)
Beijing Pins Medical Co., Ltd
Not applicable
60
Hefei, Beijing, Guangzhou, Changsha, Nanjing, Jinan, Chengdu
2026-05-16
Not yet open
A Single-Arm, Open-Label Phase Ia/Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of FS-207 in Patients With Advanced Solid Tumors With High Microsatellite Instability (MSI-H)
NCT07593144Advanced Solid Tumors
Foresight Therapeutics (Hefei) Co., Ltd.
Phase 1
156
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Changchun
2026-05-15
Recruiting
Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD
NCT07632677Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis, Metabolic Dysfunction-associated Fatty Liver Disease
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
10,000
Bengbu, Hefei, Wuhu, Guangzhou, Shenzhen, Nanning, Zunyi, Haikou
2026-05-15
Not yet open
A Study to Evaluate the Safety, PK, and Immunogenicity of Recombinant Human Hyaluronidase in Healthy Subjects
NCT07484893Healthy Adult Male
Shanghai Henlius Biotech
Phase 1
24
Hefei
2026-05-14
Recruiting
Study of Food Effects of VV913 Capsules in Chinese Healthy Volunteers
NCT07565792Healthy Volunteers
Vigonvita Life Sciences
Phase 1
12
Hefei
2026-05-11
Recruiting
Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
NCT07379047GIST - Gastrointestinal Stromal Tumor, Advanced
Ningbo Newbay Technology Development Co., Ltd
Phase 2/3
255
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Shijiazhuang
2026-05-11
Recruiting
A Phase I Clinical Trial to Evaluate the Pharmacokinetic Characteristics of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Moderate Renal Impairment and Normal Renal Function
NCT07694869Healthy Participants, Participants With Moderate Renal Impairment
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1
16
Hefei
2026-05-10
Recruiting
A Clinical Study of Cizutamig in Thyroid Eye Disease
NCT07597200Thyroid Eye Disease, TED
Candid Therapeutics
Phase 1
38
Hefei, Beijing, Fuzhou, Foshan, Guangzhou, Changsha, Wuhan, Nanchang
2026-05-08
Recruiting
SAfety and eFfectiveness of cathetER Ablation for Atrial Fibrillation With Intracranial Hemorrhage (SAFER-AF)
NCT07316270AF - Atrial Fibrillation, Intracranial Hemorrhage, Spontaneous
Beijing Anzhen Hospital
Not applicable
646
Hefei, Beijing, Xiamen, Harbin, Changchun, Xi'an
2026-05-06
Not yet open
Protective Efficacy , Immunogenicity and Safety of the Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).
NCT07611513Hand, Foot, and Mouth Disease(HFMD), Herpangina
Sinovac Biotech Co., Ltd
Phase 3
6,000
Hefei, Fujian, Henan, Hubei, Sichuan
2026-05
Not yet open
Phase I Clinical Study of NouvNeu001 Injection for the Treatment of Moderate-to-Advanced Parkinson's Disease in Patients Who Have Previously Undergone Deep Brain Stimulation or Deep Brain Nucleus Lesioning Surgery
NCT07550374Parkinson's Disease (PD)
iRegene Therapeutics Co., Ltd.
Phase 1
10
Hefei
2026-05
Not yet open
A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus
NCT07557927Discoid Lupus Erythematosus
Kunming Pharmaceuticals, Inc.
Phase 2
100
Hefei, Beijing, Chongqing, Guangzhou, Changsha, Shenyang, Kunming, Hangzhou
2026-04-30
Recruiting
Investigating Functional Changes in the Frontotemporal Cortex of Patients With Major Depressive Disorder Following Electroconvulsive Therapy or Magnetic Seizure Therapy Using Functional Near-infrared Spectroscopy (fNIRS)
NCT07533773Major Depressive Disorder (MDD)
The Second Hospital of Anhui Medical University
Not applicable
60
Hefei
2026-04-30
Recruiting
TIS for NSSI in Adolescent Depression
NCT07554755Temporal Interference Stimulation, Non Suicidal Self Injury, Major Depressive Disorder
The Second Hospital of Anhui Medical University
Not applicable
60
Hefei
2026-04-30
Not yet open
Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 Compared With EU-Phesgoยฎ
NCT07495930Health Adult Subjects
Shanghai Henlius Biotech
Phase 1
24
Hefei
2026-04-30
Recruiting
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
NCT07571161Alzheimer Disease
Eli Lilly and Company
Phase 3
140
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei
2026-04-30
Recruiting
A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.
NCT07450599High-risk Localized Prostate Cancer
Bayer
Phase 2
250
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Shijiazhuang, Harbin, Zhengzhou
2026-04-27
Recruiting
Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study
NCT07440537Cutaneous Lupus Erythematosus (CLE)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
105
Hefei, Beijing, Chongqing, Fuzhou, Dongguan, Guangzhou, Shijiazhuang, Zhengzhou
2026-04-27
Not yet open
A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases
NCT07583030Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE), Relapsed/Refractory IgG4-Related Disease (r/r IgG4-RD), Progressive Multiple Sclerosis (PMS), Relapsed/Refractory Myasthenia Gravis(r/r MS)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1
44
Hefei, Beijing, Wuhan, Taiyuan
2026-04-20
Recruiting
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT07385703Adenocarcinoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
752
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Wuwei
2026-04-15
Active, closed
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
NCT07663903Severe Hemophilia A
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Phase 3
60
Tianjin, Fuyang, Fuzhou, Ganzhou, Guangzhou, Hefei, Huai'an, Jinan
2026-04-14
Recruiting
Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV913 Capsules
NCT07507838Healthy Volunteers
Vigonvita Life Sciences
Phase EARLY_PHASE1
24
Hefei
2026-04-13
By invitation
A Post-marketing Observational Study of Oral Cholera Vaccine
NCT07300462Diarrhea
Shanghai United Cell Biotechnology Co., Ltd
Phase 4
6,000
Hefei, Beijing, Wuhan, Nanjing, Jinan
2026-04-10
Not yet open
Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT)
NCT07481656Acute Brain Injuries, Moderate to Severe Traumatic Brain Injury
Anhui Provincial Hospital
Phase 4
160
Hefei
2026-04-10
Not yet open
Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin
NCT07502001Overweight, Obesity
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
42
Hefei
2026-04-08
Recruiting
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
NCT07416474Non-Small Cell Lung Cancer
RemeGen Co., Ltd.
Phase 3
574
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Dongguan, Guangzhou
2026-04-03
Active, closed
A Study of CS060380 Tablets in Patients With MASH and Obesity
NCT07466017Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity
Cascade Pharmaceuticals, Inc
Phase 2
130
Hefei, Guangzhou, Shijiazhuang, Nanjing, Shanghai, Hangzhou, Ningbo, Wenzhou
2026-04-02
Not yet open
Simultaneous Vs Staged VPS and CP :A Multi-cnter RCT.
NCT07462676Ventriculoperitoneal Shunt (VPS), Cranioplasty
Anhui Provincial Hospital
Not applicable
300
Hefei
2026-04-01
Recruiting
UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic Anemia
NCT07530380AIHA - Warm Autoimmune Hemolytic Anemia, UCART
The Second Hospital of Anhui Medical University
Phase EARLY_PHASE1
15
Hefei
2026-04
Recruiting
Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas
NCT07407803Plexiform Neurofibroma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
177
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning, Guiyang
2026-03-31
Active, closed
A Phase I Study of SIM0532 in Adult Participants With Advanced Solid Tumors
NCT07749703Histologically or Cytologically Confirmed Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
346
Hefei, Shenyang, Jinan, Shanghai, Hangzhou
2026-03-31
Recruiting
Transcranial Direct Current Stimulation for Depression
NCT07500064Depression
The Second Hospital of Anhui Medical University
Not applicable
50
Hefei
2026-03-30
Recruiting
Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery
NCT07383909Aortic Dissection Type A
Fujian Medical University
Not applicable
1,312
Hefei, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Dalian
2026-03-29
Recruiting
A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
NCT07490262Hepatocellular Carcinoma (HCC)
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Phase 2/3
680
Hefei, Shanghai
2026-03-27
Recruiting
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
NCT07405151Oesophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC
Phase 1/2
60
Hefei, Beijing, Xiamen, Zhengzhou, Xuzhou, Jinan, Hangzhou
2026-03-27
Recruiting
A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity
NCT07478822Upper Limb Spasticity
Chongqing Claruvis Pharmaceutical Co., Ltd.
Phase 3
300
Beijing, Chengdu, Guangdong, Guangzhou, Hefei, Huai'an, Kaifeng, Kunming
2026-03-27
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Eli Lilly and Company
Phase 2
1,431
Binzhou, Changzhou, Chengdu, Chongqing, Foshan, Guangzhou, Harbin, Hefei
2026-03-26
Recruiting
Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia
NCT07388680Radiation-induced Lung Injury, Immune-related Pneumonia
Beijing Continent Pharmaceutical Co, Ltd.
Phase 2/3
298
Hefei, Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou, Maoming, Shenzhen
2026-03-26
Recruiting
A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy
NCT07487896Advanced Esophageal Squamous Cell Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3
440
Anqing, Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou
2026-03-24
Not yet open
Efficacy and Safety of Sublingual Immunotherapy for Allergic Rhinitis Due to House Dust Mites
NCT07475715Allergic Rhinitis Due to Dust Mite
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
Phase 2
250
Hefei, Nanning, Haikou, Jingzhou, Wuhan, Changsha, Hengyang, Nanchang
2026-03-23
Recruiting
Anti CD19 Gene Therapy for B-cell Lymphoma
NCT07211048B-cell Lymphoma
Anhui Provincial Hospital
Not applicable
18
Hefei
2026-03-20
Recruiting
Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07787273Locally Advanced Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy, Camrelizumab
Hefei Cancer Hospital of the Chinese Academy of Sciences
Phase 2
84
Hefei
2026-03-20
Recruiting
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and the Food Effect of HSK55879 Tablets in Healthy Subjects.
NCT07521345Healhty
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
46
Hefei
2026-03-20
Recruiting
tACS for Self-Other Boundary in Schizophrenia
NCT07818668Schizophrenia / Schizoaffective Disorder
Chunyan Zhu
Not applicable
100
Hefei
2026-03-17
Not yet open
Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial
NCT07449910Acute Ichemic Stroke, Anterior Cerebral Artery Stroke, Baricitinib
The First Affiliated Hospital of University of Science and Technology of China
Phase 2/3
750
Hefei
2026-03-17
Recruiting
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT07291076Hepatocellular Carcinoma (HCC)
Bristol-Myers Squibb
Phase 1/2
198
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Nanyang
2026-03-16
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045Obesity or Overweight
Hoffmann-La Roche
Phase 3
2,000
Zhenjiang, Xianyang, Jinan, Beijing, Changchun, Hefei, Herbin, Huizhou
2026-03-16
Recruiting
Effect of EIT-guided PEEP in ARDS Patients
NCT06990477ARDS (Acute Respiratory Distress Syndrome)
Southeast University, China
Not applicable
2,400
Hefei, Shanghai, Guangzhou, Zhengzhou, Hangzhou, Nanjing, Xuzhou, Nanchang
2026-03-13
Not yet open
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML
NCT07486479Acute Myeloid Leukemia (AML)
The First Affiliated Hospital of Soochow University
Phase 3
204
Hefei, Luoyang, Wuhan, Changzhou, Huai'an, Jingjiang, Lianyungang, Nanjing
2026-03-10
Not yet open
Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets
NCT07486453Primary Hypertension
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Phase 1
60
Hefei
2026-03-09
Recruiting
Phase II Study of RC1416 Injection in COPD
NCT07402551Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Nanjing RegeneCore Biotech Co., Ltd.
Phase 2
180
Hefei, Suzhou, Chongqing, Xiamen, Guangzhou, Huizhou, Jiangmen, Qingyuan
2026-03-06
Recruiting
ART Trial: Transcatheter J-VALVE Versus Surgery for Aortic Regurgitation Therapy
NCT07453407Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,250
Hefei, Beijing, Fuzhou, Guangzhou, Zhengzhou, Hong Kong, Wuhan, Changsha
2026-03-05
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496Lupus Erythematosus, Systemic
Janssen Research & Development, LLC
Phase 3
600
Beijing, Changsha, Cheng Du Shi, Dongguan, Guangzhou, Hangzhou, Hefei, Jinhua
2026-03-05
Active, closed
Health Coaching for Self-Management in Maintenance Hemodialysis Patients
NCT07685626End-Stage Kidney Disease (ESKD), Maintenance Hemodialysis (MHD)
Anhui Medical University
Not applicable
60
Hefei
2026-03-01
Not yet open
Mapsd Dual-target cTBS (Auditory Cortex and M1) for Generalized Anxiety Disorder
NCT07403591Generalized Anxiety Disorder
Anhui Medical University
Not applicable
60
Hefei
2026-03-01
Active, closed
Efficacy and Underlying Mechanisms of Group-Based Natural Psychotherapy for Anxiety Disorder
NCT07518264Obsessive - Compulsive Disorder
Beijing HuiLongGuan Hospital
Not applicable
60
Hefei
2026-03-01
Recruiting
Impact of Pringle Maneuver on Postoperative Gallbladder Diseases After Hepatectomy
NCT07452848Gallbladder Diseases, Cholelithiasis
West China Hospital
Observational
2,000
Hefei, Chongqing, Guangzhou, Harbin, Wuhan, Nanjing, Tianjin
2026-03-01
Not yet open
Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT07464587Chronic Obstructive Pulmonary Disease
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
800
Bozhou, Chizhou, Hefei, Chongqing, Fuzhou, Zhangzhou, Lanzhou, Foshan
2026-03
Not yet open
A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs
NCT07483684HER2 IHC3+ Advanced Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
142
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Meizhou
2026-03
Recruiting
A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07327229Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Antengene Biologics Limited
Phase 1/2
132
Hefei, Beijing, Fuzhou, Xiamen, Lanzhou, Langfang, Shijiazhuang, Anyang
2026-02-27
Recruiting
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
NCT07391657Relapsed Refractory Multiple Myeloma
AstraZeneca
Phase 3
508
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hefei, Nanchang, Nanjing
2026-02-23
Not yet open
Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)
NCT07393438Multidrug-Resistant Tuberculosis, Rifampicin-resistant Tuberculosis, MDR-TB, RR-TB
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
120
Hefei, Shanghai
2026-02-21
Recruiting
Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis
NCT07431060Langerhans Cell Histiocytosis (LCH)
West China Second University Hospital
Not applicable
120
Chengdu, Guiyang, Hefei, Jiangxi, Kunming, Nanning, รœrรผmqi, Xi'an
2026-02-13
Recruiting
Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer
NCT07367516Esophageal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
105
Hefei, Beijing, Fuzhou, Lanzhou, Shantou, Nanning, Guangxi, Zunyi
2026-02-12
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07363694Moderate to Severe Chronic Obstructive Pulmonary Disease
Pfizer
Phase 2/3
1,156
Chizhou, Fuyang, Hefei, Beijing, Guangzhou, Huizhou, Xinxiang, Hohhot
2026-02-11
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT07369011Sleep Apnea, Obstructive, Obesity, Overweight
Eli Lilly and Company
Phase 3
800
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Kunming
2026-02-10
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190Overweight, Obesity
Eli Lilly and Company
Phase 3
900
Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Hefei, Huzhou
2026-02-10
Recruiting
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
NCT07353931Osteoarthritis, Overweight or Obesity
Eli Lilly and Company
Phase 3
900
Beijing, Bengbu, Changchun, Changsha, Chongqing, Hangzhou, Hefei, Jinan
2026-02-09
Recruiting
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
NCT07412756Depressive Disorder, Major
Eli Lilly and Company
Phase 3
1,000
Beijing, Changsha, Chengdu, Guangzhou, Haidian District, Hefei, Huzhou, Jining
2026-02-09
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886Obesity, Overweight
Eli Lilly and Company
Phase 3
1,980
Beijing, Chengdu, Guangzhou, Hefei, Jinan, Luoyang Shi, Nanchang, Nanjing
2026-02-06
Recruiting
A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
NCT07253142Non Small Cell Lung Cancer, Small Cell Lung Cancer
Shanghai Henlius Biotech
Phase 2
120
Hefei, Fu'zhou, Guangzhou, Nanning, Cangzhou, Harbin, Xinxiang, Wuha
2026-02-05
Recruiting
A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
NCT07276958Healthy, Systemic Lupus Erythematosus, Rheumatoid Arthritis
Eli Lilly and Company
Phase 1
68
Beijing, Changsha, Hefei, Shanghai, Wenzhou, Wuhan
2026-02-04
Recruiting
Clinical Study of AFN50 Injection in the Autoimmune Diseases
NCT07408336Autoimmune Diseases
AlphaNa Bioscience Company Limited
Phase EARLY_PHASE1
18
Hefei
2026-02-04
Recruiting
Efficacy of Montelukast on STEMl Patients
NCT07320625Myocardial Infarction (MI)
Shanghai Zhongshan Hospital
Phase 3
512
Dalian, Shanghai, Fuzhou, Guangdong, Haโ€™erbin, Hefei, Hunan, Shenyang
2026-02-01
Recruiting
Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)
NCT07383818HR Positive/HER2 Low Breast Cancer
First Affiliated Hospital of Zhejiang University
Phase 2
111
Harbin, Hefei, Shanghai, Xi'an, Zhengzhou
2026-02-01
Active, closed
Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET
NCT07450560Solid Tumor
Shuanghu Yuan
Observational
30
Hefei
2026-02-01
Not yet open
A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE๏ผ‰
NCT07274137Overweight or Obesity
MindRank AI Ltd
Phase 3
738
Beijing, Changchun, Changde, Changsha, Datong, Dongyang, Ganzhou, Hefei
2026-02
Active, closed
A Prospective, Randomized, Blind, Controlled Multicenter Clinical Study Comparing the Effectiveness of Preventive Ventricular Arrhythmia Ablation on the Prognosis After Left Ventricular Assist Device (LVAD) Surgery.
NCT07589738CHF - Congestive Heart Failure
The First Affiliated Hospital of Anhui Medical University
Not applicable
90
Hefei
2026-01-31
Recruiting
Study of the Safety, Tolerability, Pharmacokinetics of VV913 Capsules in Chinese Healthy Participants
NCT07372703Healthy Volunteers
Vigonvita Life Sciences
Phase 1
56
Hefei
2026-01-29
Recruiting
Study of Predicting Lymph Node Metastasis of High-risk Prostate Cancer by Artificial Intelligence Multi-omics Analysis
NCT07112599Prostate Cancer, Lymph Node Cancer Metastatic, Artificial Intelligence (AI)
Anhui Medical University
Observational
2,000
Hefei
2026-01-25
Recruiting
Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
NCT07317934Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Innostellar Biotherapeutics Co.,Ltd
Phase 3
388
Hefei, Beijing, Chongqing, Guangzhou, Shantou, Zhongshan, Xingtai, Harbin
2026-01-14
Recruiting
Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion
NCT07185022Stroke, Cerebrovascular Disorders, Brain Diseases, Nervous System Diseases
The Second Hospital of Anhui Medical University
Not applicable
282
Fuyang, Hefei, Lu'an, Liuzhou, Lishui
2026-01-06
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
Pfizer
Phase 3
1,410
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Huizhou, Jiangmen, Nanning
2026-01-06
Recruiting
Study of the Safety, Tolerability, Pharmacokinetics of VV261 Tablets in Chinese Healthy Volunteers
NCT07302269Healthy Volunteers
Vigonvita Life Sciences
Phase 1
58
Hefei
2026-01-04
Active, closed
SAL0137 Phase I Study in in Healthy Participants With or Without Elevated Lp(a)
NCT07745114Healthy Participants, Elevated Lp(a)
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Phase 1
144
Hefei
2026-01-04
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb
Phase 2/3
590
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning
2026-01-02
Active, closed
Construction and Validation of an Intelligent Ultrasound Diagnostic System for the Spectrum of Neuroblastoma in Children
NCT07549425Neuroblastic Tumors
The Children's Hospital of Zhejiang University School of Medicine
Observational
300
Hefei, Suzhou, Kunming, Hangzhou, Wenling
2026-01-01
Rows per page Showing 101–200 of 875
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/hefei?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 875 of those studies with a site in Hefei.

How many clinical trials are recruiting in Hefei?

512 of the 875 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 137 have not yet opened recruitment, 211 are active but closed to new participants, and 15 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.